CBDV (Cannabidivarin): What It Is and What Research Shows

Overview

CBDV (cannabidivarin) is a plant cannabinoid closely related to CBD. A 2021 review describes it as the propyl analogue of CBD, meaning its molecule has a slightly shorter side chain, and says it has drawn attention as a possible treatment for disabling neurological conditions. [1] Most of what is known comes from animals and a few small human studies. This guide uses plain evidence labels: approved medicine, promising but limited, mixed, insufficient evidence, preclinical (cells/animals only), no good evidence of benefit and marketing claim. "Proper evidence not found" means we looked and found nothing usable. For the main related compound, see CBD.

What it is and where it comes from

CBDV is one of the cannabinoids derived from the Cannabis sativa plant. [1] Proper evidence not found, in the sources read, for typical amounts in plant material or products; composition varies from batch to batch, and only a batch-specific lab report can show it. See how to read a cannabis COA.

Regulatory category

Approved medicine: Proper evidence not found. The medicines covered on this site are Epidiolex (CBD), dronabinol, nabilone and nabiximols; see approved cannabinoid medicines. We did not find a regulator page listing CBDV as an approved medicine. Legal status of CBDV products: not verified; see cannabis laws by country.

What research shows

• Animal models of epilepsy and brain disease. A 2020 systematic review of minor cannabinoids found cannabidivarin displayed efficacy in models of Huntington's disease and epilepsy. [2] Label: preclinical (cells/animals only). Do not apply this to people.
• Adults with focal seizures (human trial). In a phase 2 randomized, placebo-controlled trial, 162 adults with inadequately controlled focal seizures were enrolled, 81 in each group. [3] Seizure frequency fell by similar amounts with CBDV (40.5%) and placebo (37.7%). [3] There were no significant differences on any secondary efficacy outcome. [3] Label: no good evidence of benefit in this population, from this trial. The authors suggest a high placebo response may have played a part, but a difference from placebo was not observed. [3]
• Rett syndrome (very small, no placebo group). A phase 1 trial enrolled five girls with Rett syndrome and drug-resistant epilepsy to study safety and tolerability. [4] Hypersomnolence (heavy sleepiness) and drooling were identified as related to CBDV. [4] Label: insufficient evidence. Five children and no control group cannot show whether CBDV works.
• Autism spectrum disorder. A phase 2 randomized, placebo-controlled trial in children is registered as of this reading with a status of recruiting. [5] Results are not available, so Proper evidence not found for CBDV treating autism. A 2025 systematic review of minor cannabinoids in psychiatric disorders found 22 preclinical studies and one clinical study in total. [6] Label: preclinical (cells/animals only) for the animal findings, which should not be applied to children.
• Pain, anxiety, sleep and other claims. Proper evidence not found. We checked PubMed and found no human trial in these areas.

Risks, adverse effects and interactions

In the focal-seizure trial, 72.8% of people taking CBDV and 48.1% taking placebo had at least one treatment-emergent adverse event; the most common were diarrhea, nausea and somnolence (sleepiness). [3] Serum liver enzyme elevations of more than three times the upper limit of normal occurred in three people taking CBDV, two of whom stopped. [3] These were prescription-style trial settings with medical monitoring, not consumer products. Liver monitoring and interactions with seizure medicines have not been studied for consumer CBDV products: Proper evidence not found. See liver considerations for cannabinoids and medicine interactions.

Special groups

Children, pregnant or breastfeeding people, and people with epilepsy should not use a CBDV product in place of prescribed treatment. Never stop or change a seizure medicine without the prescriber. Proper evidence not found for CBDV safety in pregnancy or breastfeeding in the sources read.

Quality and labeling

CBDV is sold in a few consumer products. Claims about seizures, autism or calming are marketing claims; the trial evidence does not support them. A certificate of analysis shows content only; see why a COA does not prove effectiveness.

Related guides

Minor cannabinoids at a glance and cannabinoids and neurological conditions.